Piérard Gérald E, Piérard-Franchimont Claudine, Delvenne Philippe
Laboaory of Skin Bioengineering and Imaging, Department of Clinical Sciences, Liège University, Liège, Belgium; Department of Dermatopathology, Unilab Lg, Liège University Hospital, Liège, Belgium.
Laboaory of Skin Bioengineering and Imaging, Department of Clinical Sciences, Liège University , Liège, Belgium.
Oncol Rev. 2015 Aug 5;9(1):278. doi: 10.4081/oncol.2015.278. eCollection 2015 Feb 10.
During the recent period, dermoscopy has yielded improvement in the early disclosure of various atypical melanocytic neoplasms (AMN) of the skin. Beyond this clinical procedure, AMN histopathology remains mandatory for establishing their precise diagnosis. Of note, panels of experts in AMN merely report moderate agreement in various puzzling cases. Divergences in opinion and misdiagnosis are likely increased when histopathological criteria are not fine-tuned and when facing a diversity of AMN types. Furthermore, some AMN have been differently named in the literature including atypical Spitz tumor, metastasizing Spitz tumor, borderline and intermediate melanocytic tumor, malignant Spitz nevus, pigmented epithelioid melanocytoma or animal-type melanoma. Some acronyms have been further suggested such as MELTUMP (after melanocytic tumor of uncertain malignant potential) and STUMP (after Spitzoid melanocytic tumor of uncertain malignant potential). In this review, such AMN at the exclusion of cutaneous malignant melanoma (MM) variants, are grouped under the tentative broad heading skin melanocytoma. Such set of AMN frequently follows an indolent course, although they exhibit atypical and sometimes worrisome patterns or cytological atypia. Rare cases of skin melanocytomas progress to loco regional clusters of lesions (agminate melanocytomas), and even to regional lymph nodes. At times, the distinction between a skin melanocytoma and MM remains puzzling. However, multipronged immunohistochemistry and emerging molecular biology help profiling any malignancy risk if present.
近年来,皮肤镜检查在早期发现各种皮肤非典型黑素细胞肿瘤(AMN)方面取得了进展。除了这种临床检查方法外,AMN的组织病理学检查对于准确诊断仍然是必不可少的。值得注意的是,AMN专家小组在各种疑难病例中仅报告了中度一致性。当组织病理学标准未得到精细调整以及面对多种AMN类型时,意见分歧和误诊的可能性可能会增加。此外,一些AMN在文献中有不同的名称,包括非典型斯皮茨瘤、转移性斯皮茨瘤、交界性和中间性黑素细胞肿瘤、恶性斯皮茨痣、色素性上皮样黑素细胞瘤或动物型黑素瘤。还提出了一些首字母缩略词,如MELTUMP(源自恶性潜能不确定的黑素细胞肿瘤)和STUMP(源自恶性潜能不确定的斯皮茨样黑素细胞肿瘤)。在本综述中,排除皮肤恶性黑色素瘤(MM)变体后的此类AMN,暂归为广义的皮肤黑素细胞瘤。这类AMN通常病程缓慢,尽管它们表现出非典型的、有时令人担忧的模式或细胞学非典型性。罕见的皮肤黑素细胞瘤病例会发展为局部病灶簇(聚集性黑素细胞瘤),甚至转移至区域淋巴结。有时,皮肤黑素细胞瘤与MM之间的区分仍然令人困惑。然而,多靶点免疫组化和新兴的分子生物学有助于评估是否存在任何恶性风险。